logo
Plus   Neg
Share
Email

CVS Health Raises, Narrows 2019 Adj. EPS Guidance - Quick Facts

CVS Health Corp. (CVS) raised and narrowed its fiscal 2019 adjusted earnings per share guidance range to $6.97 to $7.05 from $6.89 to $7.00. The company also raised and narrowed adjusted operating income guidance range to $15.22 billion to $15.40 billion from $15.16 billion to $15.36 billion. Analysts polled by Thomson Reuters expect the company to report profit per share of $6.98. Analysts' estimates typically exclude special items.

For the third-quarter, adjusted earnings per share was $1.84 compared to $1.73, a year ago. On average, 24 analysts polled by Thomson Reuters expected the company to report profit per share of $1.77, for the quarter.

Third-quarter total revenues increased to $64.81 billion from $47.49 billion, prior year. Analysts expected revenue of $62.99 billion, for the quarter. Adjusted revenues increased 37.1 percent. Revenue growth was primarily driven by the impact of the Aetna Acquisition, as well as increased volume and brand name drug price inflation in both the Pharmacy Services and Retail/LTC segments.

Shares of CVS Health Corp. were up 3% in pre-market trade on Wednesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT